STAT+: Many patient, consumer reps on FDA advisory panels have ties to groups funded by pharma, analysis finds

Summary

An analysis found that nearly 40% of FDA advisory committee meetings over a 20-year period included patient or consumer representatives with ties to pharma-funded advocacy groups, raising questions about potential conflicts of interest in the advisory process.